Analgesics
Antiandrogens
Antihistamines
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
TMPRSS2 inh.
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
c19early.org COVID-19 treatment researchZafirlukastZafirlukast (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta

 
    
  
Zafirlukast for COVID-19
1 study from 11 scientists
40 patients in 1 country
COVID-19 Zafirlukast studies. May 2025. c19early.org
0 0.5 1 1.5+ All studies -100% Hospitalization -15% Viral clearance -23% RCTs -100% Late -100% Favorszafirlukast Favorscontrol
Recent:
Hamdan
Ghobain.
Jan 10
Hamdan et al., Turkish Journal of Pharmaceutical Sciences, doi:10.4274/tjps.galenos.2024.49768 In silico Evaluation of H1-Antihistamine as Potential Inhibitors of SARS-CoV-2 RNA-dependent RNA Polymerase: Repurposing Study of COVID-19 Therapy
In Silico study showing that H1RA antihistamines, including bilastine, fexofenadine, mizolastine, rupatadine, terfenadine, and the leukotriene receptor antagonists montelukast and zafirlukast, may inhibit SARS-CoV-2 RNA-dependent RNA poly..
Dec 31
2022
Ghobain et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.11.016 The efficacy of Zafirlukast as a SARS-CoV-2 helicase inhibitor in adult patients with moderate COVID-19 Pneumonia (pilot randomized clinical trial)
100% higher ICU admission (p=1), 9% worse 7-point scale results (p=0.48), 15% longer hospitalization (p=0.47), and 23% worse viral clearance (p=0.48). RCT 40 hospitalized patients with moderate COVID-19 pneumonia showing no significant difference with zafirlukast treatment compared to placebo. Authors suggest that the lack of efficacy might be related to timing of drug administration re..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit